Kura Oncology (NASDAQ: KURA) revenue
Kura Oncology reported revenue of $67.5m for fiscal 2025, 25.2% more than in fiscal 2024 ($53.9m).
Fiscal 2025 is the highest of the 3 fiscal years on record for Kura Oncology.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $67.5m | +25.2% | −$303.6m | −449.9% |
| 2024 | $53.9m | — | −$193.2m | −358.5% |
| 2023 | $0.0m | — | −$165.8m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Kura Oncology revenue compared with its sector
By revenue for its latest fiscal year, Kura Oncology ranks 317th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Kura Oncology, 25.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 315th | Vir Biotechnology | $68.6m | −7.6% |
| 316th | Intellia Therapeutics | $67.7m | 16.9% |
| 317th | Kura Oncology | $67.5m | 25.2% |
| 318th | Enanta Pharmaceuticals | $65.3m | −3.4% |
| 319th | Nuvation Bio | $62.9m | 699.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Kura Oncology
- How much revenue did Kura Oncology make in fiscal 2025?
- Kura Oncology reported revenue of $67.5m for fiscal 2025, compared with $53.9m in fiscal 2024.
- What was the best year for revenue at Kura Oncology?
- Of its last 3 fiscal years, fiscal 2025, with $67.5m.
- Where does Kura Oncology rank in its sector by revenue?
- It ranks 317th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Kura Oncology come from?
- From the annual report (Form 10-K) that Kura Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Kura Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Kura Oncology: the Kura Oncology page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.